Professor Michael J Cork

BSc MB PhD FRCP

Clinical Medicine, School of Medicine and Population Health

Professor of Dermatology

Michael Cork
Profile picture of Michael Cork
M.J.Cork@sheffield.ac.uk
+44 114 215 9576 (Clerical Assistant - Les Hunter)

Full contact details

Professor Michael J Cork
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I joined the University of Sheffield in 1991 as a lecturer in dermatology whilst continuing as a practising dermatologist for the NHS in Sheffield. I had previously been a Registrar in Dermatology at the Royal Hallamshire Hospital, Sheffield, and before that a Registrar in Respiratory General Medicine at Leeds General Infirmary.

I have been closely involved with research in many areas of dermatology; including Atopic Eczema(dermatitis), Psoriasis, Vitiligo and the Genetics of Skin Disease. My major current research work is aimed at identifying gene–environment interactions in the development of atopic dermatitis leading to skin barrier breakdown and the understanding of how topical agents interact with the skin barrier; using this information to enhance the treatment of atopic dermatitis.

I am currently Head of Sheffield Dermatology Research in the School of Medicine & Population Health at the University of Sheffield and am Honorary Consultant Dermatologist to both Sheffield Children´s Hospital NHS Foundation Trust and to Sheffield Teaching Hospitals NHS Foundation Trust; my time is evenly split between the University and the NHS.

Research interests

My research interests are inflammatory skin disorders including: atopic dermatitis (atopic eczema), psoriasis, alopecia areata and vitiligo. The group which includes both clinical and non-clinical staff has identified genetic variants associated with all of these diseases.

Internationally, Sheffield Dermatology Research is one of the leading groups translating basic dermatological science into new treatments for the clinic. Examples include `Skin Protease Inhibitors´ and `Vitamin A Metabolic Pathway Inhibitors´. In 2001, with help from The Wellcome Trust, the group formed a `spin-out´ company called `Molecular SkinCare´, with the aim of developing these treatments.

Another major focus of the group is the effect of topical pharmaceuticals, cosmetics and oils on the structure and function of the skin barrier. Research in this area comprises investigation of the skin barrier defect associated with skin disorders such as atopic dermatitis, how skin barrier defects develop and how to treat or repair the skin barrier defect. This includes the determination of the effect of topical agents/products on the skin of volunteers visiting our clinical diagnostic `skin laboratory´, where we can measure specific properties of the skin barrier, non-invasively, using an array of specialised equipment. These results are then correlated with variants in the genes that determine the structure and function of the skin barrier.

Research conducted by Sheffield Dermatology Research is at the interface between the clinic, academia and industry. Work has been funded by charities, including: The Wellcome Trust, British Skin Foundation and Psoriasis Association; also by the Kuwait Ministry of Health; and by pharmaceutical/cosmetics companies; including Astellas, Johnson & Johnson and Stiefel-GSK.

Publications

Show: Featured publications All publications

Journal articles

Chapters

  • Danby S, Bedwell C & Cork MJ (2014) Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders RIS download Bibtex download
  • Cork MJ & Danby S (2011) The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd.. RIS download Bibtex download

Reports

  • Danby SG, Ewence A, Rumsby P, Cork MJ, Williams HC, Rockett L & Davey HMSAUIII-PP (2011) A systematic review of skin irritation and tap water RIS download Bibtex download

All publications

Journal articles

Chapters

  • Danby SG & Cork MJ (2018) pH in Atopic Dermatitis, pH of the Skin: Issues and Challenges (pp. 95-107). S. Karger AG RIS download Bibtex download
  • Danby S, Bedwell C & Cork MJ (2014) Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders RIS download Bibtex download
  • Cork MJ & Danby SG (2012) Current and Future Trends: Skin Diseases and Treatment In Benson HAE & Watkinson AC (Ed.), Topical and Transdermal Drug Delivery Wiley RIS download Bibtex download
  • Cork MJ & Danby S (2011) The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd.. RIS download Bibtex download
  • Cork MJ, Moustafa M, Danby S, Vasilopoulos Y, Tazi-Ahnini R, Ward SJ, Hadgraft J, Lane ME, Guy R & MacGowan A (2009) Skin Barrier Dysfunction in Atopic Dermatitis, Basic and Clinical Dermatology (pp. 211-240). Informa Healthcare RIS download Bibtex download
  • Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane M, Moustafa M, Guy R, MacGowan A, Tazi-Ahnini R & Ward SJ (2009) Epidermal Barrier Dysfunction in Atopic Dermatitis In Rawlings L (Ed.), Skin Moisturization USA: Informa Healthcare USA Inc.. RIS download Bibtex download

Conference proceedings papers

  • Berdyshev E, Goleva E, Danby S, Bronoff A, Agueusop I, Zahn J, Gloaguen E, Bissonnette R, Boguniewicz M, Ong P , Zhang A et al (2024) Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 144(8) (pp S48-S48) RIS download Bibtex download
  • Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) 55 Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 143(11) (pp S342-S342) RIS download Bibtex download
  • Siegfried EC, Cork MJ, Boguniewicz M, Deleuran M, Simpson EL, Chen Z, Clearfield D, Shah P & Marco AR (2023) 410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_3) RIS download Bibtex download
  • Paller AS, Eichenfield LF, Silverberg JI, Cork MJ, Bangert C, Irvine AD, Weidinger S, Barbarot S, Fan H, Alderfer J , Koppensteiner H et al (2023) 383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure. British Journal of Dermatology, Vol. 188(Supplement_3) RIS download Bibtex download
  • Paller AS, Siegfried EC, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Khokhar FA, Bansal A & Prescilla R (2023) 437 Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial. British Journal of Dermatology, Vol. 188(Supplement_3) RIS download Bibtex download
  • Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) 411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_3) RIS download Bibtex download
  • Siegfried EC, Cork MJ, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) 337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_2) RIS download Bibtex download
  • Pinter A, Cork MJ, Siegfried EC, Arkwright PD, Wollenberg A, Eichenfield LF, Ramien M, Khokhar FA, Chen Z, Zhang A & Cyr SL (2023) Dupilumab Treatment is Not AssociatedWith an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 yearsWithModerate-to-Severe Atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 100-101) RIS download Bibtex download
  • Paller A, Siegfried E, Sidbury R, Lockshin B, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB100-AB100) RIS download Bibtex download
  • Wollenberg A, Cork MJ, Flohr C, Bewley A, Blauvelt A, Hong-H C-H, Imafuku S, Schuttelaar M-LA, Simpson E, Soong W , Amoudruz P et al (2023) SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 58-58) RIS download Bibtex download
  • Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB221-AB221) RIS download Bibtex download
  • Wollenberg A, Cork MJ, Hong HC-H, Taveira CM, Kurbasic A, Vacko E & Paller AS (2023) PROGRESSIVE AND SUSTAINED DISEASE CONTROL IN PATIENTS WITH ATOPIC DERMATITIS (AD) AGED 12-17 YEARS TREATED WITH TRALOKINUMAB FOR 52 WEEKS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 30-30) RIS download Bibtex download
  • Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W, Almgren P, Carlsson A & Blauvelt A (2023) Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB190-AB190) RIS download Bibtex download
  • Wollenberg A, Paller AS, Bewley A, Cork M, Hong C-H, Soong W, Oland CB, Taveira CM, Gjerum L & Blauvelt A (2023) LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54) RIS download Bibtex download
  • Paller AS, Ramien M, Cork MJ, Simpson EL, Lee LW, Eichenfield LF, Coleman A, Gherardi G, Tian T, Zhang A & Cyr SL (2023) LONG-TERM DUPILUMAB TREATMENT IS NOT ASSOCIATED WITH AN INCREASED OVERALL RISK OF INFECTIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN AN OPENLABEL EXTENSION STUDY. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54) RIS download Bibtex download
  • Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB62-AB62) RIS download Bibtex download
  • Paller A, Eichenfield LF, Cork MJ, Bangert C, Irvine AD, Weidinger S, Johnson S, Lazariciu I & Koppensteiner H (2023) Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 77-77) RIS download Bibtex download
  • Cork MJ, Paller AS, Siegfried EC, Xiao J, Prescilla R, Dubost-Brama A & Bansal A (2023) EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 53-53) RIS download Bibtex download
  • Cork MJ, Leung DYM, Ong P, Danby SG, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Praestgaard A, Bologna G & Zhang A (2023) Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 143(11) (pp S342-S342) RIS download Bibtex download
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Marco AR (2023) Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB40-AB40) RIS download Bibtex download
  • Weidinger S, Pinter A, Cork MJ, Arkwright PD, Simpson EL, Praestgaard A, Shumel B & Rodriguez Marco A (2023) Sequence of improvement in atopic dermatitis signs and symptoms in patients aged 6 months to 17 years treated with dupilumab. ALLERGY, Vol. 78 (pp 196-196) RIS download Bibtex download
  • Leung DY, Cork MJ, Ong P, Danby S, Ramirez-Gama M, Garcia S, Taylor P, Zahn J, Bologna G & Zhang A (2023) Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis. ALLERGY, Vol. 78 (pp 194-194) RIS download Bibtex download
  • Riechmann J, Ajtai SS & Cork MJ (2023) Allergy profile for patients receiving dupilumab for severe atopic dermatitis. ALLERGY, Vol. 78 RIS download Bibtex download
  • Cork MJ, Beck LA, Deleuran M, Hong HC-H, Adam DN, Hussain I, Zhang H, Shabbir A, Rodriguez Marco A & Levit NA (2022) Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1014-1014) RIS download Bibtex download
  • Cork MJ, Wollenberg A, Siegfried E, Chen Z, Levit NA & Rodriguez Marco A (2022) Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1059-1059) RIS download Bibtex download
  • Cork MJ, Papp KA, Deleuran M, Pink AE, Reich K, Biswas P, Chan G, Feeney C, Chiu WS & Randall RM (2022) Long-term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 72-72) RIS download Bibtex download
  • Flohr C, Jones A, Rosala-Hallas A, Beattie P, Baron S, Browne F, Brown S, Gach J, Hearn R, Esdaile B , Cork M et al (2022) A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT). BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 13-14) RIS download Bibtex download
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R , Lockshin B et al (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E173-E173) RIS download Bibtex download
  • Paller AS, Cork MJ, Siegfried EC, Guttman-Yassky E, Simpson EL, Soong W, Xiao J, Wang Z, Chuang C-C, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E159-E160) RIS download Bibtex download
  • Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E90-E91) RIS download Bibtex download
  • Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 142(8) (pp B17-B17) RIS download Bibtex download
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Marco AR (2022) Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E112-E113) RIS download Bibtex download
  • Weidinger S, Cork M, Reich A, Beiber T, Gilbert S, Brennan N, Wilson R, Quaratino S & Porter-Brown B (2022) A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E96-E96) RIS download Bibtex download
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Zhang H, Wang Z & Rodriguez Marco A (2022) Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E104-E105) RIS download Bibtex download
  • Paller AS, Cork MJ, Siegfried EC, Simpson EL, Wollenberg A, Gonzalez ME, Sun Y, O'Malley JT & Bansal A (2022) Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 12-12) RIS download Bibtex download
  • Cork M, Beck L, Bissonnette R, Wollenberg A, Simpson E, Praestgaard A, Aamodt K & Rossi A (2022) Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 69-69) RIS download Bibtex download
  • Cork MJ, Yosipovitch G, Silverberg JI, Praestgaard A, Zhang H, Wang Z & Rossi AB (2022) Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 79-79) RIS download Bibtex download
  • Paller A, Blauvelt A, Soong W, Imafuku S, Hong C, Schuttelaar MLA, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Schneider S et al (2022) Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E145-E146) RIS download Bibtex download
  • Danby SG, Andrew PV, Taylor RN, Kay LJ, Chittock J, Pinnock A, Ulhaq I, Fasth A, Carlander K, Holm T , Cork MJ et al (2022) EFFECTS OF EMOLLIENT CREAMS ON THE SKIN BARRIER OF PATIENTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 102 (pp 35-36) RIS download Bibtex download
  • Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 161 52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE) (pp a68.2-a6a69) RIS download Bibtex download
  • Cork MJ, Wollenberg A, Siegfried EC, Arkwright PD, Chen Z, Levit NA, Marco AR & Radwan A (2021) Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1659-1659) RIS download Bibtex download
  • Paller A, Wollenberg A, Cork M, Siegfried E, Chen Z, Vakil J, Levit N, Marco AR & Radwan A (2021) Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1687-1688) RIS download Bibtex download
  • Cork MJ, Lockshin B, Blauvelt A, Chen Z, Vakil J & Khokhar FA (2021) Fifty-two-week laboratory safety findings from an open-label extension study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E121-E121) RIS download Bibtex download
  • Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E115-E116) RIS download Bibtex download
  • Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120) RIS download Bibtex download
  • Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120) RIS download Bibtex download
  • Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB136-AB136) RIS download Bibtex download
  • Paller A, Cork MJ, Marcoux D, Zhang H, Chuang C, Zhang A & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 141(5) (pp S84-S84) RIS download Bibtex download
  • Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Bansal A & Shumel B (2021) LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED >= 6-< 12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS). ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 59-59) RIS download Bibtex download
  • Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Prescilla R, Delevry D, O'Malley JT & Bansal A (2021) LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED >= 6 TO < 12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 60-60) RIS download Bibtex download
  • Cork MJ, Thaci D, Eichenfield L, Arkwright PD, Bastian M, Chen Z, Delevry D, O'Malley JT & Bansal A (2021) Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 14-14) RIS download Bibtex download
  • Lio P, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell M, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E110-E110) RIS download Bibtex download
  • Bewley A, Thyssen JP, Chiu WS, Rojo R, Biswas P, Feeney C, DiBonaventura M, Misery L, Stander S & Cork M (2021) Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E72-E73) RIS download Bibtex download
  • Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB141-AB141) RIS download Bibtex download
  • Lio PA, Spergel JM, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O'Connell MA, Zang C & Takiya L (2021) Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB97-AB97) RIS download Bibtex download
  • Simon JC, Barbarot S, Gooderham M, Simpson E, Kurbasic A, Olsen CK, Cork MJ & Silverberg JI (2021) The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 56-56) RIS download Bibtex download
  • Silverberg JI, Barbarot S, Gooderham M, Simon JC, Simpson E, Kurbasic A, Olsen CK & Cork MJ (2021) Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E65) RIS download Bibtex download
  • Silverberg JI, Cork M, Wollenberg A, Katoh N, Steffensen LA, Kurbasic A, Olsen CK, Kuznetsova A, Osterdal ML, Vilsboll AW , Deleuran M et al (2021) Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E64) RIS download Bibtex download
  • Danby SG, Andrew PV, Pinnock A, Kay L, Chittock J & Cork MJ (2021) LOWERING SKIN SURFACE PH WITH A TOPICAL ZINC LACTOBIONATE PREPARATION CONTAINING PHYSIOLOGIC LIPIDS IMPROVES SKIN BARRIER STRUCTURE AND FUNCTION IN ADULTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 51-51) RIS download Bibtex download
  • Wollenberg A, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, Vakil J & Khokhar FA (2021) Laboratory safety of dupilumab in paediatric patients aged >= 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E122-E123) RIS download Bibtex download
  • Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ , Sach TH et al (2021) A RANDOMISED CONTROLLED TRIAL OF DAILY EMOLLIENT DURING INFANCY FOR PREVENTING ECZEMA - RESULTS OF THE BEEP TRIAL. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 7-8) RIS download Bibtex download
  • Danby SG, Andrew P, Kay L, Pinnock A, Chittock J, Brown K & Cork MJ (2020) An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB71-AB71) RIS download Bibtex download
  • Cork MJ, Lockshin B, Morren M-A, Etoh T, Chen Z, Rossi AB, Lu Y, Bansal A & Shabbir A (2020) Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB39-AB39) RIS download Bibtex download
  • Flohr C, Beattie P, Cork M, Brown S, Burton T, Gholam K, Griffiths C, Ingram J, Irvine A, Langan S , Manca A et al (2020) The use of systemic immunomodulatory agents in the treatment of children and adolescents with atopic eczema: lessons from the UK-Irish Atopic Eczema Systemic Therapy (A-STAR) Register. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-148) RIS download Bibtex download
  • Shabbir A, Paller AS, Lockshin B, Cork MJ, Morren M, Kataoka Y, Chen Z, Rossi AB & Lu Y (2020) Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 140(7) (pp S60-S60) RIS download Bibtex download
  • Simpson EL, Sinclair R, Forman S, Wollenberg A, Asch R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Magnolo N , Maari C et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183(4) (pp E105-E106) RIS download Bibtex download
  • McPherson T, Cork M, Michaelis L, Flohr C, Davis L, Petrovic M, Hennessy L, Rajkovic I & Hudson R (2020) A real-world observational study to describe National Health Service resource use for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents aged 6-17 years. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-147) RIS download Bibtex download
  • Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 139(5) (pp s104-s104), 8 May 2019 - 11 May 2019. View this article in WRRO RIS download Bibtex download
  • Cork MJ, Eichenfield LF, Blauvelt A, Rosmarin D, Hussain I, Davis JD, Li M, Zhang Q, Gadkari A, Eckert L , Kamal MA et al (2019) Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 139(5) (pp S104-S104) RIS download Bibtex download
  • de Bruin-Weller M, Eckert L, Simpson EL, Cork MJ, Ardeleanu M, Chen Z, Shumel B, Rossi AB, Graham NMH, Pirozzi G & Gadkari A (2019) Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 17 (pp 116-116) RIS download Bibtex download
  • Chittock J, Brown K, Cork MJ & Danby SG (2018) Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model. BRITISH JOURNAL OF DERMATOLOGY, Vol. 179(1) (pp E35-E36) View this article in WRRO RIS download Bibtex download
  • Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 155-155) RIS download Bibtex download
  • Cork MJ, Thaci D, Davis JD, Zhang Q, Akinlade B, Graham NMH, Pirozzi G & Bansal A (2017) An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 67-68) RIS download Bibtex download
  • Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P , Kingo K et al (2017) Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 15 (pp 79-79) RIS download Bibtex download
  • Byers RA, Maiti R, Danby SG, Pang EJ, Mitchell B, Carré MJ, Lewis R, Cork MJ & Matcher SJ (2017) Characterizing the microcirculation of atopic dermatitis using angiographic optical coherence tomography. Proceedings of SPIE, Vol. 10037 View this article in WRRO RIS download Bibtex download
  • De Bruin-Weller M, Gadkari A, Simpson E, Cork M, Puig L, Girolomoni G, Wollenberg A, Chen Z, Radin A, Shumel B , Ardeleanu M et al (2017) DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN ATOPIC DERMATITIS PATIENTS INADEQUATELY CONTROLLED, INTOLERANT, OR INADVISABLE FOR CYCLOSPORINE-A. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, Vol. 119(5) (pp S94-S95) RIS download Bibtex download
  • Danby S, Wan H, Chittock J, Brown K, Wigley A & Cork M (2016) Characterisation of the skin barrier defect in atopic dermatitis using in vivo ATR-FTIR spectroscopy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 136(9) (pp S182-S182) RIS download Bibtex download
  • Cooke A, Cork M, Victor S, Campbell M, Danby S, Chittock J & Lavender T (2015) A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 173 (pp 153-153) RIS download Bibtex download
  • Danby S, Brown K, Higgs-Bayliss T, Chittock J & Cork M (2014) The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 171 (pp 57-58) RIS download Bibtex download
  • Chalmers JR, Simpson EL, Chen YY, Cork MJ, Brown SJ, Thomas KS, Williams HC & Grp BEEPS (2014) Feasibility study of Barrier Enhancement For Eczema Prevention (BEEP). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E8-E9) RIS download Bibtex download
  • Higgs-Bayliss T, Brown K, Chittock J, Cork MJ & Danby SG (2014) Noninvasive assessment of the lipid structure and water holding properties of the stratum corneum in vivo by ATR-FTIR using a fibre optic probe in patients with atopic dermatitis and healthy controls. BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E29-E29) RIS download Bibtex download
  • Chalmers JR, Thomas KS, Montgomery A, Sach T, Boyle RJ, Ridd MJ, Simpson EL, Cork MJ, Brown SJ, Lawton S , Thornton J et al (2014) A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E32-E32) RIS download Bibtex download
  • Shareef MS, Albenali L, Cork MJ & Clark SM (2013) A difficult case of atopic eczema: useful learning points. BRITISH JOURNAL OF DERMATOLOGY, Vol. 169 (pp 120-120) RIS download Bibtex download
  • Danby S, Chittock J, Martin KM, Cork MJ & Tierney NK (2013) Chymotrypsin-like protease activity in the stratum corneum is increased in atopic dermatitis and upon washing with soap. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 68(4) (pp AB172-AB172) RIS download Bibtex download
  • Cork MJ (2012) Skin barrier breakdown in atopic dermatitis: the effect of topical products. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 34(4) (pp 363-364) RIS download Bibtex download
  • Albenali L, Danby S, Moustafa M, Chittock J, Kennedy K, Shackley F & Cork MJ (2012) Vitamin D supplementation improves atopic dermatitis and atopic dermatitis complicated by eczema herpeticum. BRITISH JOURNAL OF DERMATOLOGY, Vol. 167 (pp 127-127) RIS download Bibtex download
  • Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 115-115) RIS download Bibtex download
  • Danby S, Al Enezi T, Chittock J, Kennedy K, Sultan A & Cork M (2011) A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 44-45) RIS download Bibtex download
  • Moustafa M, Holden C, Athavale P, Cork M, Messenger A & Gawkrodger DJ (2009) Patch testing is a useful investigation in children with eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 125-125) RIS download Bibtex download
  • Al Enezi T, Sultan A, Chittock J, Moustafa M, Danby S & Cork MJ (2009) Breakdown of the skin barrier induced by aqueous cream: implications for the management of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 115-116) RIS download Bibtex download
  • Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: a new treatment for atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 30-31) RIS download Bibtex download
  • Danby S, Moustafa M, MacGowan AL, Ward SJ & Cork MJ (2009) Skin protease inhibitors: A new treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 60(3) (pp AB67-AB67) RIS download Bibtex download
  • Carr J, Akram M, Sultan A, Hunter L, Moustafa M, Messenger AG, Fenton P & Cork MJ (2008) Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 114-114) RIS download Bibtex download
  • Harcastle NJ, MacGowan AL, Henderson JK, Cork MJ & Ward SJ (2008) Vitamin A metabolic pathway inhibition: a new therapeutic approach to treating psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 118-118) RIS download Bibtex download
  • Cork MJ, Varghese J, Hadcraft J, Lane M, Ferguson A, Moustafa M, Guy RH & Ward S (2007) Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - Implications for therapy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 127 (pp S45-S45) RIS download Bibtex download
  • Kemp EH, McDonagh AJG, Wengraf DA, Messenger AG, Gawkodger DJ, Cork MJ & Tazi-Ahnini R (2007) Severe alopecia areata is associated with a functional polymorphism in the PTPN22 gene. IMMUNOLOGY, Vol. 120 (pp 70-70) RIS download Bibtex download
  • Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2007) The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 56(2) (pp AB69-AB69) RIS download Bibtex download
  • Simon M, Tazi-Ahnini R, Jonca N, Cork MJ & Serre G (2006) Reduced and abnormal proteolysis of corneodesmosomal proteins in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 126 (pp 116-116) RIS download Bibtex download
  • Lovewell TRJ, Cork MJ, Wengraf DA, Messenger AG, McDonagh AJG & Tazi-Ahnini R (2006) A study on the effect of genetic variants of the autoimmune regulator (AIRE) promoter, on AIRE activity and downstream Aire-regulated genes. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 250-250) RIS download Bibtex download
  • Vasilopoulos Y, Cork MJ, Sagoo GS, Ward SJ, Duff GW & Tazi-Ahnini R (2006) A synonymous single nucleotide polymorphism in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 235-235) RIS download Bibtex download
  • Cork M, Robinson D, Vasilopoulos Y & Ferguson A (2006) Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 54(3) (pp AB3-AB3) RIS download Bibtex download
  • Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 605-605) RIS download Bibtex download
  • Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, Tazi-Ahnini R & Ward SJ (2005) Treatment of atopic dermatitis from a skin barrier perspective. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 611-611) RIS download Bibtex download
  • Cork M (2005) Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 52(3) (pp P9-P9) RIS download Bibtex download
  • Cork MJ, Timmins J, Holden C, Carr J, Berry V, Tazi-Ahnini R & Ward SJ (2004) An audit of adverse drug reactions to aqueous cream in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 151 (pp 57-58) RIS download Bibtex download
  • Simon M, Tazi-Ahnini R, Cork MJ & Serre G (2003) Abnormal proteolysis of corneodesmosin in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 121(6) (pp 1568-1568) RIS download Bibtex download
  • Tazi-Ahnini R, Vasilopoulos Y, Henderson JK, Murphy R, Williams H, Ward SJ, Duff GW & Cork MJ (2003) Role of variants within genes regulating the skin barrier in the pathogenesis of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 149 (pp 4-4) RIS download Bibtex download
  • Wengraf DA, McDonagh AJG, Cork MJ, Gawkrodger D, Messenger AG & Tazi-Ahnini R (2003) Genetic analysis of the autoimmune regulator (aire) gene: potential role of aire in susceptibility to alopecia universalis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 849-850) RIS download Bibtex download
  • McDonagh AJG, Messenger AG, Birch MP, Cork MJ & Tazi-Ahnini R (2003) Alopecia areata: age at onset, atopy & disease associations. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 866-867) RIS download Bibtex download
  • Price VH, Stenn KS, Duvic M, Goldsmith LA, Cork MJ, Happle R, Kalabokes V & Moshell AN (1999) Introduction. Journal of Investigative Dermatology Symposium Proceedings, Vol. 4(3) (pp 199-199) RIS download Bibtex download
  • CORK M (1996) The role of in atopic eczema: treatment strategies. Journal of the European Academy of Dermatology and Venereology, Vol. 7 (pp S31-S37) RIS download Bibtex download
  • Paller A, Blauvelt A, Soong W, Imafuku S, Hong C-H, Schuttelaar M, Amoudruz P, Kurbasic A, Soldbro L, Lophaven K , Cork M et al () Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, Vol. 6(2) (pp s29-s29) RIS download Bibtex download

Reports

  • Danby SG, Ewence A, Rumsby P, Cork MJ, Williams HC, Rockett L & Davey HMSAUIII-PP (2011) A systematic review of skin irritation and tap water RIS download Bibtex download

Posters

  • Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. RIS download Bibtex download
  • Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Praestgaard A, Prescilla R, Wang Z & Rodriguez Marco A (2023) 41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. RIS download Bibtex download
  • Simpson E, Paller A, Wollenberg A, Bewley A, Cork M, Hong C-H, Soong W & Almgren P (2023) 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. RIS download Bibtex download
  • Paller A, Siegfried E, Sidbury R, Cork M, Pinter A, Xiao J, Stanton S, Khokhar F, Bansal A & Prescilla R (2023) 42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. RIS download Bibtex download
  • Siegfried E, Cork MJ, Lockshin B, Boguniewicz M, Uppal S, Vass M, Khokhar FA, Bansal A, Sierka D & Cyr S (2023) 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. RIS download Bibtex download
  • Katibi OS, Andrew P, Poyner A, Pinnock A, Brown K, Byers R, Cork M & Danby S (2023) P24 Emollient use and effects on cutaneous allergen reactions: a preliminary study. RIS download Bibtex download
  • Cork M, Bissonnette R, Ramirez-Gama M, Taylor P, Praestgaard A, Levit N, Rossi A & Zhang A (2023) P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes. RIS download Bibtex download
  • Paller AS, Cork MJ, Wollenberg A, Siegfried EC, Gonzalez ME, Lockshin B, Khokhar FA, Chen Z, Gonzalez T, Simcox E & Prescilla R (2023) P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6 months–5 years with moderate-to-severe atopic dermatitis. RIS download Bibtex download
  • Paller AS, Cork MJ, Flohr C, Bangert C, Weidinger S, Nesnas J, Farooqui SA, Biswas P, Watkins M & Koppensteiner H (2023) P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND. RIS download Bibtex download
  • Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Quaratino S, Wilson R & Porter-Brown B (2023) 392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis. RIS download Bibtex download
  • Weidinger S, Cork M, Reich A, Bieber T, Lucchesi D, Rynkiewicz N, Sainson RCA, Chen R, Prandi F, van Krinks C , Stebegg M et al (2023) 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay. RIS download Bibtex download
  • Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Brennan N, Wilson R, Lucchesi D, Rynkiewicz N, Stebegg M & Porter-Brown B (2023) 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis. RIS download Bibtex download
  • Ong P, Cork MJ & Armstrong A (2022) 34326 Real-world analysis of skin infections and antimicrobial use among patients with atopic dermatitis before and after initiation of dupilumab treatment. RIS download Bibtex download
  • Weidinger S, Bieber T & Cork M (2022) 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis. RIS download Bibtex download
  • Winder N & Cork M (2022) 33569 Optimization of common hand cleansers for protection from viral spread and occupational hand dermatoses. RIS download Bibtex download
  • Paller A, Eichenfield LF & Cork MJ (2022) 34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program. RIS download Bibtex download
  • Weidinger S, Bieber T, Cork M, Reich A, Brennan N, Quaratino S, Wilson R & Porter-Brown B (2022) 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD). RIS download Bibtex download
  • Simpson E, Blauvelt A, Silverberg JI, Cork M, Katoh N, Mark T, Schneider S & Wollenberg A (2022) LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. RIS download Bibtex download
  • Paller AS, Weidinger S, Cork MJ, Marcoux D, Katoh N, Zhang H, Rossi AB, Shumel B, Zhang A, Prescilla R & Chao J (2021) 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. RIS download Bibtex download
  • Paller AS, Cork MJ, Marcoux D, Wollenberg A, Prescilla R, Chen Z, Rossi AB & Shumel B (2021) 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD). RIS download Bibtex download
  • Cork MJ, Thaçi D, Eichenfield L, Arkwright PD, Chen Z, Delevry D, O’Malley JT & Bansal A (2021) 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). RIS download Bibtex download
  • Cork MJ, Lockshin B, Blauvelt A, Chen Z, Khokhar FA, Bansal A & Prescilla R (2021) 26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). RIS download Bibtex download
Teaching interests

My teaching interests within The University include medical undergraduate lecturing and in-clinic training plus postgraduate researcher training and mentoring. I also lecture to related courses at other universities, such as the MSc in Dermatology at Cardiff and at major international and national conferences in the field of dermatology. In addition I undertake a large number of atopic eczema related educational presentations at local, national and international level to a wide range of audiences including; pharmacists, general practitioners, hospital nurses, community nurses, midwives, paediatricians, practice nurses and patient support charities (e.g. National Eczema Society, Skin Care Campaign and Psoriasis Association).

Education of Children with Skin Diseases:

I have developed a special interest in `translating´ the complex pathophysiology of skin disease into cartoons and language that can be understood by a child of six. I presented these to the National Eczema Society and the Skin Care Campaign. I have written papers for these charities describing the content of the lectures, for example Cork et al 2000; 2002 "Skin Wars". I use the cartoons in my clinics to teach children and their parent about skin diseases. The medical students that sit-in during my clinics, suggested I incorporated the "Skin Wars" cartoons into their lectures because they made dermatology exciting. The "Skin Wars" cartoons have been disseminated to many other dermatology departments. I have assigned all commercial profits from use of the "Skin Wars" cartoons to the National Eczema Society. The "Skin Wars" teaching approach was cited as being an innovative approach to education by the judges in the Hospital Doctor Dermatology Team of the Year Awards, which our paediatric dermatology team won in 2001. This teaching method was also highlighted in the National Eczema Society Health Care Professionals Award 2004.

Professional activities and memberships
  • Member of the National Institute of Clinical Excellence (NICE) clinical guideline development group for the treatment of Atopic Eczema in children.
  • Advisor, Lecturer and developer of educational materials for the National Eczema Society, Skin Care Campaign, Psoriasis Association and Allergy UK.
  • Wellcome Trust Translational Grants Reviewer & Expert Panel member.
  • Grant Reviewer, British Skin Foundation, Psoriasis Association and Wellcome Trust.
  • Fellow of the Royal College of Physicians, London and Edinburgh.
  • Member of British Association of Dermatologists.
  • Member of European Academy of Dermatology and Venereology.
  • Member of British Society for Investigative Dermatology.
  • Member of European Society for Dermatological Research.
  • Member of British Society for Paediatric Dermatology.
  • Member of Dowling Dermatology Society.
  • Professional Member of the National Eczema Society.
  • Member of The Council (board) of the Psoriasis Association.
  • South Yorkshire Biotech Enterprise Network (SYBEN): York Pharma – Biotech company of the year, 2006.
  • Yorkshire Forward Bioscience Yorkshire Annual Awards: Molecular Skin Care: Recognised for Outstanding Achievements in Bioscience. Awarded to the company who has made the greatest advances in Yorkshire in 2005.
  • Leader of the team awarded ‘Health Care Professional Team of the Year’ by the National Eczema Society in 2004.
  • Leader of the team awarded ‘Hospital Doctor Dermatology Team of the Year’ 2001.
Enquiries

For Teaching & Academic Supervisory Enquiries, Post-Graduate and Undergraduate (i.e. PATs) please email:
Les Hunter & cc to Prof. Michael J. Cork
For Research Enquiries (including Pharmacological, Cosmetic & Academic) please email: Les Hunter & cc to Prof. Michael J. Cork
For Children’s Clinical NHS Enquiries please email: Elaine Cox & cc to Prof. Michael J. Cork
For Adult Clinical NHS Enquiries please email: Lucy Lowe & cc to Prof. Michael J. Cork